• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Vir. Parasite-Mediated Upregulation of NK Cell-Derived Gamma Interferon Protects against Severe Highly Pathogenic H5N1 Influenza Virus Infection

Emily

Editor, Senior Moderator
http://jvi.asm.org/cgi/content/abstract/85/17/8680

Parasite-Mediated Upregulation of NK Cell-Derived Gamma Interferon Protects against Severe Highly Pathogenic H5N1 Influenza Virus Infection<sup>
dtri.gif
</sup> Kevin B. O'Brien,<sup>1</sup><sup>,2</sup> Stacey Schultz-Cherry,<sup>1</sup><sup>*</sup>, and Laura J. Knoll<sup>2</sup><sup>*</sup> Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee 38105,<sup>1</sup> Department of Medical Microbiology and Immunology, University of Wisconsin, Madison, Wisconsin 53706<sup>2</sup>
Received 17 May 2011/ Accepted 23 June 2011
Outbreaks of influenza A viruses are associated with significant<sup> </sup>human morbidity worldwide. Given the increasing resistance to<sup> </sup>the available influenza drugs, new therapies for the treatment<sup> </sup>of influenza virus infection are needed. An alternative approach<sup> </sup>is to identify products that enhance a protective immune response.<sup> </sup>In these studies, we demonstrate that infecting mice with the<sup> </sup>Th1-inducing parasite Toxoplasma gondii prior to highly pathogenic<sup> </sup>avian H5N1 influenza virus infection led to decreased lung viral<sup> </sup>titers and enhanced survival. A noninfectious fraction of T.<sup> </sup>gondii soluble antigens (STAg) elicited an immune response similar<sup> </sup>to that elicited by live parasites, and administration of STAg<sup> </sup>2 days after H5N1 influenza virus infection enhanced survival,<sup> </sup>lowered viral titers, and reduced clinical disease. STAg administration<sup> </sup>protected H5N1 virus-infected mice lacking lymphocytes, suggesting<sup> </sup>that while the adaptive immune response was not required for<sup> </sup>enhanced survival, it was necessary for STAg-mediated viral<sup> </sup>clearance. Mechanistically, we found that administration of<sup> </sup>STAg led to increased production of gamma interferon (IFN-
gamma.gif
)<sup> </sup>from natural killer (NK) cells, which were both necessary and<sup> </sup>sufficient for survival. Further, administration of exogenous<sup> </sup>IFN-
gamma.gif
alone enhanced survival from H5N1 influenza virus infection,<sup> </sup>although not to the same level as STAg treatment. These studies<sup> </sup>demonstrate that a noninfectious T. gondii extract enhances<sup> </sup>the protective immune response against severe H5N1 influenza<sup> </sup>virus infections even when a single dose is administered 2 days<sup> </sup>postinfection.
 
Last edited by a moderator:
Back
Top Bottom